Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,100 shares of the biopharmaceutical company’s stock after purchasing an additional 8,400 shares during the period. Regeneron Pharmaceuticals comprises approximately 2.2% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 11th largest holding. Rhenman & Partners Asset Management AB’s holdings in Regeneron Pharmaceuticals were worth $20,298,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at $31,000. Caitlin John LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at $34,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $38,000. Finally, Berbice Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. Evercore upped their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Canaccord Genuity Group raised their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Barclays began coverage on Regeneron Pharmaceuticals in a research report on Friday. They issued an “overweight” rating and a $923.00 price objective for the company. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Finally, Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $802.27.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock worth $4,142,738 over the last three months. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $759.82 on Friday. The stock has a market capitalization of $80.33 billion, a P/E ratio of 18.28, a PEG ratio of 2.04 and a beta of 0.41. The business has a 50 day simple moving average of $770.81 and a two-hundred day simple moving average of $688.75. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company posted $12.07 earnings per share. The business’s revenue was up 2.5% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.